Patents by Inventor Jorg Kallen

Jorg Kallen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1H-QUINAZOLINE-2,4-DIONES
    Publication number: 20130296332
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Application
    Filed: July 1, 2013
    Publication date: November 7, 2013
    Inventors: Hans ALLGEIER, Yves AUBERSON, David CARCACHE, Philipp FLOERSHEIM, Christel GUIBOURDENCHE, Wolfgang FROESTL, Jörg KALLEN, Manuel KOLLER, Henri MATTES, Joachim NOZULAK, David ORAIN, Johanne RENAUD
  • 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy
    Patent number: 8513268
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: August 20, 2013
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • 1H-QUINAZOLINE-2,4-DIONES
    Publication number: 20110294818
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Application
    Filed: July 28, 2011
    Publication date: December 1, 2011
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • 3-imidazolyl-indoles for the treatment of proliferative diseases
    Patent number: 8053457
    Abstract: The invention relates to 3-heterocyclyl indolyl compounds of formula I capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively: wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: November 8, 2011
    Assignee: Novartis AG
    Inventors: Andreas Boettcher, Nicole Buschmann, Pascal Furet, Jean-Marc Groell, Jorg Kallen, Joanna Hergovich Lisztwan, Keiichi Masuya, Lorenz Mayr, Andrea Vaupel
  • N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide
    Patent number: 8012988
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: September 6, 2011
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • 1H-QUINAZ0LINE-2,4-DIONES
    Publication number: 20100144747
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Application
    Filed: September 29, 2009
    Publication date: June 10, 2010
    Inventors: Hans ALLGEIER, Yves AUBERSON, David CARCACHE, Philipp FLOERSHEIM, Christel GUIBOURDENCHE, Wolfgang FROESTL, Jörg KALLEN, Manuel KOLLER, Henri MATTES, Joachim NOZULAK, David ORAIN, Johanne RENAUD
  • 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases
    Publication number: 20100125064
    Abstract: The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula I, wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.
    Type: Application
    Filed: March 27, 2008
    Publication date: May 20, 2010
    Applicant: NOVARTIS AG
    Inventors: Andreas Boettcher, Nicole Buschmann, Pascal Furet, Jean-Marc Groell, Jorg Kallen, Joanna Hergovich Lisztwan, Keiichi Masuya, Lorenz Mayr, Andrea Vaupel
  • Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands
    Patent number: 7655666
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: February 2, 2010
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • 1H-Quinazoline-2,4-Diones
    Publication number: 20080153836
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Application
    Filed: April 10, 2006
    Publication date: June 26, 2008
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jorg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
    Publication number: 20050165218
    Abstract: The present invention relates RORa in crystallized form and methods for the preparation thereof. The invention also provides a three-dimensional model of RORa and means for the design of RORa modulators. Ligands binding to RORa are also provided.
    Type: Application
    Filed: April 28, 2003
    Publication date: July 28, 2005
    Inventors: Rene Beerli, Brigitte Fournier, Jorg Kallen, Jean-Marc Schlaeppi
  • Melvinolin derivatives
    Patent number: 6818638
    Abstract: Mevinolin derivatives wherein the lactone ring is modified have interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1 interactions.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: November 16, 2004
    Assignee: Novartis AG
    Inventors: Rolf Baenteli, Wilfried Bauer, Sylvain Cottens, Claus Ehrhardt, Ulrich Hommel, Jörg Kallen, Josef Gottfried Meingassner, François Nuninger, Gabriele Weitz Schmidt
  • Lymphocyte function antigen-1 antagonists
    Patent number: 6630492
    Abstract: Mevinolin compounds for use in the treatment or prevention of autoimmune diseases, inflammation, ischemia/reperfusion injury and graft rejection. Such compounds bind to the LFA-1 I-domain and thereby inhibit LFA-1/ICAM-1 or LFA-1/ICAM-3 interactions.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: October 7, 2003
    Assignee: Novartis AG
    Inventors: Wilfried Bauer, Sylvain Cottens, Dieter Geyl, Gabriele Weitz-Schmidt, Jörg Kallen, Ulrich Hommel
  • Mevinolin derivatives
    Publication number: 20030087903
    Abstract: Mevinolin derivatives wherein the lactone ring is modified have interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1 interactions.
    Type: Application
    Filed: July 11, 2002
    Publication date: May 8, 2003
    Inventors: Rolf Baenteli, Wilfried Bauer, Sylvain Cottens, Claus Ehrhardt, Ulrich Hommel, Jorg Kallen, Josef Gottfried Meingassner, Francois Nuninger, Gabriele Weitz Schmidt
  • Process for the production of 4-hydroxy-3,5-dibromobenzaldehyde
    Patent number: 3996291
    Abstract: Production of 4-hydroxy-3,5-dibromobenzaldehyde reacting p-cresol with bromine, converting the 2,6-dibromo-p-cresol obtained as the first reaction product into 4-hydroxy-3,5-dibromobenzal bromide by further bromination and hydrolysing the latter.
    Type: Grant
    Filed: March 21, 1975
    Date of Patent: December 7, 1976
    Assignee: Ciba-Geigy Corporation
    Inventors: Henri Dietrich, Jorg Kallen, Gottfried Seifert